Skip to main content

Evoke Pharma, Inc. (EVOK)

NASDAQ: EVOK · IEX Real-Time Price · USD
1.34
+0.05 (3.88%)
After-hours:Sep 24, 2021 7:25 PM EDT
1.29
0.02 (1.57%)
At close: Sep 24, 4:00 PM
Market Cap43.79M
Revenue (ttm)350,076
Net Income (ttm)-9.29M
Shares Out32.39M
EPS (ttm)-0.32
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume148,143
Open1.27
Previous Close1.27
Day's Range1.24 - 1.35
52-Week Range0.96 - 5.00
Beta1.18
AnalystsBuy
Price Target9.00 (+597.7%)
Est. Earnings DateNov 9, 2021

About EVOK

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was inc...

IndustryPharmaceuticals
IPO DateSep 25, 2013
CEODavid Gonyer
Employees5
Stock ExchangeNASDAQ
Ticker SymbolEVOK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for Evoke Pharma stock is "Buy." The 12-month stock price forecast is 9.00, which is an increase of 597.67% from the latest price.

Price Target
$9.00
(597.67% upside)
Analyst Consensus: Buy

News

Evoke Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

SOLANA BEACH, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced t...

3 weeks ago - GlobeNewsWire

Chewy CEO Sumit Singh said online pet retailer wants to evoke same feelings as Disney World

The online pet retailer developed a cult following for its fast shipping and automatic deliveries of food and supplies.

Other symbols:CHWYDIS
1 month ago - CNBC

What's Up With Evoke Pharma's Stock Popping Off Friday?

Evoke Pharma Inc (NASDAQ: EVOK) shares are trading higher by 23.1% at $1.38 after the company reported better-than-expected second-quarter EPS results. Evoke Pharma reported quarterly losses of 7 cents ...

1 month ago - Benzinga

Evoke Pharma Reports Second Quarter 2021 Financial Results

Approximately 162% growth in product sales, 152% growth in prescriptions and 57% increase in new prescribers for Gimoti ®

1 month ago - GlobeNewsWire

Evoke Pharma and EVERSANA Announce Support of The International Foundation for Gastrointestinal Disorders' (IFFGD) Au...

Participating and Sponsorship in Upcoming Digestive Health Virtual Walk Participating and Sponsorship in Upcoming Digestive Health Virtual Walk

1 month ago - GlobeNewsWire

Evoke Pharma Launches Gimoti® Patient and Physician Experience Program

Program intends to expand awareness and trial of GIMOTI among non-prescribing healthcare providers Program intends to expand awareness and trial of GIMOTI among non-prescribing healthcare providers

2 months ago - GlobeNewsWire

Evoke Pharma, EVERSANA and The International Foundation for Gastrointestinal Disorders Announce Membership into IFFGD...

Extends commitment toward supporting patients experiencing Diabetic Gastroparesis through focused collaborations and Sponsorship of the 30th Anniversary Digestive Health Virtual Walk Extends commitment ...

2 months ago - GlobeNewsWire

Evoke Pharma and EVERSANA Announce Positive Findings from Second GIMOTI® Market Research Study

Results demonstrate continued increased awareness and intent to prescribe GIMOTI Results demonstrate continued increased awareness and intent to prescribe GIMOTI

3 months ago - GlobeNewsWire

Evoke Pharma Announces FDA Orange Book Listing of U.S. Patent for Gimoti®

SOLANA BEACH, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced th...

3 months ago - GlobeNewsWire

Evoke Pharma and EVERSANA Launch Social Media Campaign for Gimoti® Nasal Spray

Evoke is committed to meeting patients online, where they search for answers

3 months ago - GlobeNewsWire

Evoke Pharma Appoints Vickie Reed to Board of Directors

SOLANA BEACH, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the...

4 months ago - GlobeNewsWire

Evoke Pharma Reports First Quarter 2021 Financial Results

Nearly 293% growth of product sales, 235% growth of prescriptions and 87% increase in new prescribers for Gimoti ®

4 months ago - GlobeNewsWire

Evoke Pharma to Report First Quarter 2021 Financial Results on May 12, 2021

SOLANA BEACH, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today...

4 months ago - GlobeNewsWire

Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a Method of Use Patent w...

New patent expands intellectual property protection for nasal delivery of metoclopramide New patent expands intellectual property protection for nasal delivery of metoclopramide

5 months ago - GlobeNewsWire

Evoke Pharma Announces a Fireside Chat with Key Opinion Leaders on the Treatment of Gastroparesis

SOLANA BEACH, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a commercial stage specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders ...

5 months ago - GlobeNewsWire

Why ContraFect, Evoke, Altimmune, Novavax Are Moving Friday

Among the health care stock movers Friday are ContraFect Corporation (NASDAQ: CFRX), Evoke Pharma, Inc. (NASDAQ: EVOK), Altimmune, Inc. (NASDAQ: ALT) and Novavax, Inc. (NASDAQ: NVAX). Here's why the sto...

Other symbols:ALTCFRXNVAX
6 months ago - Benzinga

Evoke Pharma, Inc. (EVOK) Reports Q4 Loss, Misses Revenue Estimates

Evoke Pharma, Inc. (EVOK) delivered earnings and revenue surprises of -125.00% and -98.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Evoke Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021

SOLANA BEACH, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, tod...

6 months ago - GlobeNewsWire

Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purcha...

SOLANA BEACH, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, anno...

8 months ago - GlobeNewsWire

Evoke Pharma Announces Pricing of Public Offering of Common Stock

SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, toda...

8 months ago - GlobeNewsWire

Evoke Pharma Announces Proposed Public Offering of Common Stock

SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, toda...

8 months ago - GlobeNewsWire

Evoke Pharma Announces Positive Findings from GIMOTI™ Market Research Study

Healthcare practitioner survey indicates physicians' awareness and intent to prescribe newly-launched product Healthcare practitioner survey indicates physicians' awareness and intent to prescribe newly...

8 months ago - GlobeNewsWire

Do Options Traders Know Something About Evoke Pharma (EVOK) Stock We Don't?

Investors need to pay close attention to Evoke Pharma (EVOK) stock based on the movements in the options market lately.

9 months ago - Zacks Investment Research

Evoke Pharma Reports Third Quarter 2020 Financial Results

Gimoti™ commercial launch underway

10 months ago - GlobeNewsWire

Evoke and EVERSANA Announce Commercial Launch of Gimoti™

Product launch provides healthcare providers a novel treatment approach for patients suffering from symptoms of acute and recurrent diabetic gastroparesis Product launch provides healthcare providers a ...

10 months ago - GlobeNewsWire